SCM
CMPX icon

Sterling Capital Management’s Compass Therapeutics CMPX Stock Holding History

Sterling Capital Management’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.79K Buy
2,642
+198
+8% +$585 ﹤0.01% 2532
2026
Q1 		$12.9K Sell
2,444
-1,383
-36% -$7.98K ﹤0.01% 2241
2025
Q4 		$20.6K Buy
3,827
+492
+15% +$2.27K ﹤0.01% 2210
2025
Q3 		$11.7K Buy
3,335
+2,060
+162% +$6.51K ﹤0.01% 2408
2025
Q2 		$3.31K Sell
1,275
-485
-28% -$1K ﹤0.01% 2733
2025
Q1 		$3.34K Sell
1,760
-1,704
-49% -$4.53K ﹤0.01% 2361
2024
Q4 		$5.02K Buy
3,464
+3,140
+969% +$5.21K ﹤0.01% 2467
2024
Q3 		$596 Buy
+324
New +$404 ﹤0.01% 2787

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Sterling Capital Management's CMPX Position: Q2 2026 in Review

Sterling Capital Management increased its Compass Therapeutics (CMPX) stake by 8.1% in Q2 2026, buying an estimated $585 and bringing the position to 2,642 shares worth $5.79K. The position accounts for ﹤0.01% of the portfolio, ranked #2532.

Sterling Capital Management first reported a position in CMPX in Q3 2024 and has held it in 8 quarters since. The position peaked at $20.6K in Q4 2025. 216 funds tracked by Wall St. Rank hold CMPX as of Q2 2026.

  • Sterling Capital Management held 2,642 shares of Compass Therapeutics worth $5.79K as of Q2 2026.
  • Sterling Capital Management bought 198 Compass Therapeutics shares in Q2 2026, an estimated $585.
  • Compass Therapeutics made up ﹤0.01% of Sterling Capital Management's portfolio in Q2 2026, its #2532 holding.
  • Sterling Capital Management first reported a position in Compass Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • Sterling Capital Management's Compass Therapeutics position peaked at $20.6K in Q4 2025.
  • 216 funds tracked by Wall St. Rank held Compass Therapeutics as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.